VTD-PACE regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[Bortezomib|bortezomib (Velcade)]], [[thalidomide]], [[dexamethasone]], [[cisplatin|Platinum (cisplatin)]], [[doxorubicin|Adriamycin (doxorubicin)]], [[cyclophosphamide]], [[etoposide]] used to treat [[multiple myeloma]] | {{PAGENAME}} refers to a regimen consisting of [[Bortezomib|bortezomib (Velcade)]], [[thalidomide]], [[dexamethasone]], [[cisplatin|Platinum (cisplatin)]], [[doxorubicin|Adriamycin (doxorubicin)]], [[cyclophosphamide]], [[etoposide]] used to treat [[multiple myeloma]].<ref name="pmid17593024">{{cite journal| author=Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al.| title=Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. | journal=Br J Haematol | year= 2007 | volume= 138 | issue= 2 | pages= 176-85 | pmid=17593024 | doi=10.1111/j.1365-2141.2007.06639.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17593024 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|V|Bortezomib (Velcade)}} | {{chemo|V|Bortezomib (Velcade)}} | ||
| Line 22: | Line 22: | ||
==Indications== | ==Indications== | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]]<ref name="pmid17593024">{{cite journal| author=Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al.| title=Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. | journal=Br J Haematol | year= 2007 | volume= 138 | issue= 2 | pages= 176-85 | pmid=17593024 | doi=10.1111/j.1365-2141.2007.06639.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17593024 }} </ref> | ||
==References== | ==References== | ||
Revision as of 20:40, 30 March 2015
|
WikiDoc Resources for VTD-PACE regimen |
|
Articles |
|---|
|
Most recent articles on VTD-PACE regimen Most cited articles on VTD-PACE regimen |
|
Media |
|
Powerpoint slides on VTD-PACE regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on VTD-PACE regimen at Clinical Trials.gov Trial results on VTD-PACE regimen Clinical Trials on VTD-PACE regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on VTD-PACE regimen NICE Guidance on VTD-PACE regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on VTD-PACE regimen Discussion groups on VTD-PACE regimen Patient Handouts on VTD-PACE regimen Directions to Hospitals Treating VTD-PACE regimen Risk calculators and risk factors for VTD-PACE regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for VTD-PACE regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VTD-PACE regimen refers to a regimen consisting of bortezomib (Velcade), thalidomide, dexamethasone, Platinum (cisplatin), Adriamycin (doxorubicin), cyclophosphamide, etoposide used to treat multiple myeloma.[1]
Regimen
VBortezomib (Velcade)
TThalidomide
DDexamethasone
PPlatinum (cisplatin)
AAdriamycin (doxorubicin)
CCyclophosphamide
EEtoposide
Indications
References
- ↑ 1.0 1.1 Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M; et al. (2007). "Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3". Br J Haematol. 138 (2): 176–85. doi:10.1111/j.1365-2141.2007.06639.x. PMID 17593024.